16
Participants
Start Date
November 30, 2011
Primary Completion Date
March 31, 2014
Study Completion Date
April 30, 2014
Tivantinib
Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
Diagnostic laboratory biomarker analysis
Correlative studies
Questionnaire administration
Ancillary studies
Quality-of-life assessment
Ancillary studies
M D Anderson Cancer Center, Houston
National Cancer Institute (NCI)
NIH